As of the latest Form 4 filed Jun 17, 2026.
What Aprea Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 11 most recent filings for APRE.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-16 | Grissinger Michael Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Gruia Gabriela Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Peters Richard Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | HENNEMAN JOHN B III Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | BIZZARI JEAN-PIERRE Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Duey Marc Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Pamukcu Rifat Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Seizinger Bernd R. Director | AAward | +3.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Gilad Oren President/CEO | AAward | +20.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | AAward | +10.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-01 | Mirza Nadeem Q. Chief Medical Officer | AAward | +6.73K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also APRE’s full analysis or the market-wide insider trading feed. The tabs above jump to APRE’s other SEC data.
Source: SEC Form 4 filings for APRE, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.